Reagent and method for inhibition of n-ras expression
CA 2205075 C · Owner: Engels, Joachim · Inventors: Ganser, Arnold; Scherr, Michaela; Uhlmann, Eugen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to enzymatic RNA molecules which cleave mutant N-ras mRNA, preferably at a NUX cleavage site (N = any base X = A, C or U), having preferably the sequences 5'-CCAACACCUGAUGAGCGUUAGCGAAACCUGCU-3' or 5'-UCCCAACCUGAUGAGCGUUAGCGAAACACCUG-3' modified derivatives thereof, pharmaceuticals containing such molecules and use of such molecules for the preparation of pharmaceuticals for the treatment of diseases involving abnormal cell growth and/or differentiation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 1997 and granted August 9, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 23, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.